NEW YORK ( TheStreet) -- SciClone Pharmaceuticals (Nasdaq: SCLN) hit a new 52-week high Monday as it is currently trading at $6.13, above its previous 52-week high of $6 with 379,901 shares traded as of 12:02 p.m. ET. Average volume has been 443,500 shares over the past 30 days.

SciClone has a market cap of $328.1 million and is part of the health care sector and drugs industry. Shares are up 42.6% year to date as of the close of trading on Friday.

SciClone Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in the People's Republic of China and internationally. The company has a P/E ratio of 13.8, above the average drugs industry P/E ratio of 13.5 and below the S&P 500 P/E ratio of 17.7.
  • Practice your SCLN trading strategies and win cash in our stock game.

TheStreet Ratings rates SciClone as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full SciClone Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan